CNS PROPHYLAXIS IN PATIENTS WITH DLBCL: A REAL WORLD EXPERIENCE ON BEHALF OF THE LYMPHOMA SUBCOMMITTEE OF THE ARGENTINE SOCIETY OF HEMATOLOGY by Warley, F., Pereyra, P., Trucco, J., Penalba, R., Kalmus, M., Korin, L., Rivarola, S., Mahuad, C., Fiad, L., Pavlovsky, M., Rodriguez, A., Cerutti, A., Arriola, J., Miodosky, M., Tannuri, K., Martinez, S., Romero, A. L., Laviano, J., Orlova, M., Avignone, A. Juarez, Altuve, J. I. García, Equiza, T. Rivero, Cristaldo, N., Tomey, F., Marquez, M., Alfonso, G., Cugliari, S., Pavlovsky, A., Stemmelin, G., Zerga, M.

Get full text

PB1865: SINGLE‐COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG) by Pagano Vilar, C., Pavlovsky, M. A., Tannuri, R. K., Enrico Mattos, A., Zerga, M., Guanchiale, L., Custidiano, R., Miroli, A., Higashigata, M., Figueroa, F., Pose Cabarcos, J., Real, J., Giordano, L., Miodosky, M., De Stefano, G., Federico, A., Klimovsky, E., Cugliari, M. S.

Get full text

RELATIONSHIP BETWEEN SOCIOECONOMIC FACTORS AND DELAY IN DIAGNOSIS AND INITIAL TREATMENT IN PATIENTS WITH DIFUSSE LARGE B CELL LYMPHOMA (DLBCL). DO THESE FACTORS IMPACT ON THE RESPO... by Zerga, M.E., Dragosky, M., Isnardi, S., Stemmelin, G., Yantorno, S., Caccione, R., Otero, V., Marquez, M., Gotta, D., Suero, A., Alfonso, G., Beligoy, L., Flores, G., Fischman, L., Martinez, M., Rodriguez, A., Diaz Velez, N., Luchetta, P., Welsh, V., Tartas, N., Schutz, N., Zoppegno, L., Bonnacorso, S., Pujol, M., Garate, G., Mahuad, C., Vicente, A., De stefano, G., Cugliari, S., Miodosky, M., Melillo, L., Fernandez, D., Kornblihtt, L., Casali, C., Aizpuria, F.

Get full text

High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL) by Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.

Get full text

Brentuximab vedotin: A retrospective multicenter analysis of its indication, safety and efficacy in Argentina by Negri Aranguren, M.F., Shanley, C., Cranco, S., Otero, V., Fiad, L., Fernandez, I., Miodosky, M., Kusminsky, G., Corso, A., Bistmans, A., Huber, M., Marull, M., Jarchum, S., Guanchiale, L., Marquez, M., Beligoy, L., Cerutti, I., Navieckas, A., Tamashiro, M., Pujol, M., Taus, R., Canosa, V., Lopez Galletti, L., Prates, M.V., Riddick, M., Pavlovsky, A.

Get full text

High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory H odgkin lymphoma ( HL ) by Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.

Get full text